Modulation of the Bile Acid Enterohepatic Cycle by Intestinal Microbiota Alleviates Alcohol Liver Disease
Dragos Ciocan,
Madeleine Spatz,
Nicolas Trainel,
Kévin Hardonnière,
Séverine Domenichini,
Françoise Mercier-Nomé,
Aurore Desmons,
Lydie Humbert,
Sylvère Durand,
Guido Kroemer,
Antonin Lamazière,
Cindy Hugot,
Gabriel Perlemuter,
Anne-Marie Cassard
Affiliations
Dragos Ciocan
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Madeleine Spatz
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Nicolas Trainel
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Kévin Hardonnière
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Séverine Domenichini
Inserm, CNRS, Institut Paris Saclay d’Innovation Thérapeutique, Université Paris-Saclay, 92296 Chatenay-Malabry, France
Françoise Mercier-Nomé
Inserm, CNRS, Institut Paris Saclay d’Innovation Thérapeutique, Université Paris-Saclay, 92296 Chatenay-Malabry, France
Aurore Desmons
Paris Center for Microbiome Medicine (PaCeMM) FHU, 75012 Paris, France
Lydie Humbert
INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP. SU, Hôpital Saint Antoine, Département de Métabobolomique Clinique, Sorbonne Université, 75012 Paris, France
Sylvère Durand
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France
Guido Kroemer
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France
Antonin Lamazière
Paris Center for Microbiome Medicine (PaCeMM) FHU, 75012 Paris, France
Cindy Hugot
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Gabriel Perlemuter
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Anne-Marie Cassard
Inserm U996, Inflammation, Microbiome and Immunosurveillance, Université Paris-Saclay, 92140 Clamart, France
Reshaping the intestinal microbiota by the ingestion of fiber, such as pectin, improves alcohol-induced liver lesions in mice by modulating bacterial metabolites, including indoles, as well as bile acids (BAs). In this context, we aimed to elucidate how oral supplementation of pectin affects BA metabolism in alcohol-challenged mice receiving feces from patients with alcoholic hepatitis. Pectin reduced alcohol liver disease. This beneficial effect correlated with lower BA levels in the plasma and liver but higher levels in the caecum, suggesting that pectin stimulated BA excretion. Pectin modified the overall BA composition, favoring an augmentation in the proportion of hydrophilic forms in the liver, plasma, and gut. This effect was linked to an imbalance between hydrophobic and hydrophilic (less toxic) BAs in the gut. Pectin induced the enrichment of intestinal bacteria harboring genes that encode BA-metabolizing enzymes. The modulation of BA content by pectin inhibited farnesoid X receptor signaling in the ileum and the subsequent upregulation of Cyp7a1 in the liver. Despite an increase in BA synthesis, pectin reduced BA serum levels by promoting their intestinal excretion. In conclusion, pectin alleviates alcohol liver disease by modifying the BA cycle through effects on the intestinal microbiota and enhanced BA excretion.